Detalhe da pesquisa
1.
Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study.
Breast Cancer Res Treat
; 195(3): 341-351, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35986801